MA-BATTERY-VENTURES
Battery Ventures, a global, technology-focused investment firm, promoted software investor Jordan Welu to the role of partner and announced a dozen other internal promotions as it expands the global reach of its venture-capital and private-equity businesses worldwide. Battery is currently investing its 13th family of funds, raised in early 2020 and capitalized at a combined $2 billion.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210915005299/en/
Welu, who joined Battery in 2014, is a B2B-tech investor who focuses on growth-stage and buyout investments in areas such as infrastructure software, cybersecurity and financial technology. He is currently involved with Battery portfolio companies Alogent, DomainTools, Forest2Market, Learnosity and Plixer. Previously, he backed Concurrent Real-Time (acquired by Spectris) and Enviance (acquired by Cority).
Prior to Battery, Welu, who is based in Boston, worked in software corporate development and finance at companies including Rogue Wave Software, a former Battery portfolio company, and Webroot. Earlier in his career, he worked in investment banking and equity research. Jordan is a graduate of Georgetown University.
Battery also named two existing team members to the role of principal: Roland Anderson, based in Boston, and Satoshi Harris-Koizumi, based in New York. Both specialize in software investments. Anderson joined Battery in 2014 and Harris-Koizumi in 2012.
There were also six promotions to vice president. These include Danel Dayan and Courtney Chow in Menlo Park; Mike Hoeksema and Viraj Parmar in New York; Lauren Wedell in Boston; and Lior Mallul in Herzliya, Israel. In addition, Battery promoted three team members to associate. These include Maximilian Jessen and Matt Klineman, based in Boston, and Diego Liranzo in New York. Earlier this year, Battery promoted Antonia Heiss, based in London, to associate. Finally, the firm announced it has hired Jenny Kang as the firm’s vice president of talent for venture- and growth-stage companies. Previously, Kang was the head of go-to-market executive recruiting at Sequoia Capital.
“Jordan’s promotion to partner, following his work with Concurrent Real-Time and Enviance, is richly deserved, as are the promotions of all the new principals, vice presidents and associates,” said Jesse Feldman, a Battery general partner who helped make the original investment in Welu’s previous employer Rogue Wave Software. “More broadly, the moves highlight Battery’s longtime preference for promoting talent from within the firm as we seek out the most promising technology investments regardless of stage, sector or geography. We’re also very excited to add Jenny Kang to our team as we continue to offer more value-added services, including recruiting and talent assistance, to our portfolio companies.”
In the last 12 months, Battery has seen seven of its portfolio companies—Affirm, Coinbase, Confluent, JFrog, Olo, Sprinklr and Sumo Logic—stage initial public offerings. Since its founding in 1983 through June 30 of this year, Battery has funded 468 companies, not including seed investments, and realized 185 M&A events and 69 IPOs in total.
About Battery Ventures
Battery partners with exceptional founders and management teams developing category-defining businesses in markets including software and services, enterprise infrastructure, online marketplaces, healthcare IT and industrial technology. Founded in 1983, the firm backs companies at all stages, ranging from seed and early to growth and buyout, and invests globally from six strategic locations: Boston; San Francisco and Menlo Park, Calif.; Herzliya, Israel; London; and New York. Follow the firm on Twitter @BatteryVentures, visit our website at www.battery.com and find a full list of Battery's portfolio companies here .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210915005299/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom